Chimerix Inc

Chimerix — Merger or Acquisition (January 2021)

26 slides from Chimerix's merger presentation, Jan 8, 2021

  1. Slide 1: Acquisition of Oncoceutics Adds Precision Oncology Pipeline with Near-term Registration Potential

    Acquisition of Oncoceutics Adds Precision Oncology Pipeline with Near - term Registration Potential

  2. Slide 2: Forward-Looking Statements

    2 Forward - Looking Statements These slides contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward - looking stateme

  3. Slide 3: Acquisition adds portfolio of precision oncology therapies

    3 Program Collaborators Preclinical Phase 1 Phase 2 Registrational FDA review Acquisition adds portfolio of precision oncology therapies 1 Recurrent diffuse midline glioma H3 K27M mutant 2 Pheochromocytoma/paraganglioma IND enabling studies ONC212 ONC201 H3 K27M - mutant glioma (orphan drug designat

  4. Slide 4: ONC201 provides attractive near-term opportunity

    4 ONC201 provides attractive near - term opportunity ▪ Unprecedented single agent activity in recurrent H3 K27M mutant glioma - Currently no effective therapeutic options for these patients ▪ Clear path to registration, pivotal data anticipated in 2021 - FDA discussions highlight path to potential a

  5. Slide 5: Recurrent H3 K27M+ glioma, a devastating disease where single agent responses are rare

    5 Recurrent H3 K27M+ recurrent glioma, a devastating disease where single agent responses are rare and lack durability ▪ Most frequent histone mutation in glioma - Frequent (>50%) in younger patients with midline brain tumors - Classified as grade IV by WHO, regardless of diffuse glioma histology -

  6. Slide 6: H3 K27M-mutant glioma: market dynamics and opportunity

    6 H3 K27M - mutant glioma: market dynamics and opportunity ▪ Addressable market - U.S. incidence (annual): ~2,000 ▪ Market research - Nearly all mid - line glioma patients tested for H3 K27M - mutation; rate to increase with targeted therapy - Oncologists consider a therapy for recurrent H3 K27M - m

  7. Slide 7: Compelling ONC201 responses in recurrent H3 K27M mutant disease drives strong KOL engagement

    7 -100 -75 -50 -25 0 25 50 75 100 B e s t c h a n g e i n t a r g e t l e s i o n ( s ) f r o m b a s e l i n e ( % ) Compelling ONC201 responses in recurrent H3 K27M mutant disease drives strong KOL engagement ▪ 30% ORR by BICR in first 30 patients ▪ Maturing data from the next 20 patients so far d

  8. Slide 8: Meaningful durability of response

    8 Meaningful durability of response Expected ≥20% ORR in registration cohort (n=50) Response Summary * ▪ Subject to change with maturing data ▪ Meaningful duration of response - mPFS among responders: > 15 months ▪ 9 responses by BICR ▪ 2 new responses by investigator assessment (to be assessed by B

  9. Slide 9: ONC201 patient: near complete tumor regression

    9 ONC201 patient: near complete tumor regression ▪ 22 - year - old with recurrent H3 K27M mutant glioma ▪ Started single agent ONC201 treatment after recurrence of tumor in March 2016 ▪ Experienced deep and durable complete regression in the primary lesion Baseline ONC201

  10. Slide 10: ONC201 partial responses have driven clinical benefit in recurrent H3 K27M-mutant glioma

    10 ▪ 55 - year - old received single agent ONC201 at recurrence following radiation therapy (RT) and temozolomide (TMZ) ▪ Objective partial response was associated with normalization of neurological deficits by NANO 1 within two cycles - Improved gait - Improved facial strength - Improved language ▪

  11. Slide 11: ONC201 median overall survival expected to compare favorably to historical controls

    11 Upon full maturation, ONC201 median overall survival data is expected to compare favorably to historical controls ONC201 OS by line of therapy in recurrent H3 K27M+ glioma patients ONC201 OS compares favorably with historical benchmarks in recurrent patients 1 ONC201 Registrational Cohort 2 * GBM

  12. Slide 12: ONC201 demonstrates attractive safety profile, oral administration

    12 ▪ Integrated safety database for NDA will consist of >350 glioma patients ▪ No discontinuations due to drug - related adverse events (AEs) ▪ Single weekly dosing until progression ▪ Safety profile and oral dosing enable: - Fixed dosing in adults - High rate of compliance - Multiple therapeutic se

  13. Slide 13: ONC201 targets ClpP and DRD2

    13 ONC201 targets ClpP and DRD2 ONC201 upregulates integrated stress response, inactivates Akt/ERK, selectively inducing tumor cell death ▪ ONC201 can selectively induce apoptosis in cancer cells by altering activity of two proteins ▪ ClpP agonism - ClpP normally degrades misfolded proteins in mitoc

  14. Slide 14: H3 K27M-mutant gliomas exhibit enhanced sensitivity to ONC201

    14 H3 K27M - mutant gliomas exhibit enhanced sensitivity to ONC201 Lowe et al., Cancers, 2019; Chi et al., Society of Neuro - Oncology, 2017; Kawakibi et al, Society of Neuro - Oncology, 2019; Koschmann et al., Pediatric Society of Neuro - Oncology 2019; Prabhu et al, Clinical Cancer Research, 2018;

  15. Slide 15: ONC201 efficacy in dopamine-secreting tumors outside the brain

    15 ONC201 efficacy in dopamine - secreting tumors outside the brain ▪ Strongest single agent responses in Ph 2 neuroendocrine trial of ONC201 observed in subset (paraganglioma) ▪ Paraganglioma are adrenal - related tumors with elevated DRD2 expression ▪ Demonstrates that efficacy is not restricted t

  16. Slide 16: Key regulatory communications: potential path to approval

    16 Key regulatory communications: potential path to approval ▪ Homogenously defined population in recurrent diffuse midline glioma, H3 K27M - mutant, as defined by cIMPACT NOW Update 2, may be acceptable for approval ▪ FDA acknowledged that “available therapy” is considered palliative (i.e. there is

  17. Slide 17: ONC201 FDA designations

    17 ONC201 FDA designations Orphan Drug Designation (ODD) (treatment of glioblastoma and treatment of malignant glioma) Fast Track Designation (FTD) for adult recurrent H3 K27M - mutant high - grade glioma Rare Pediatric Disease Designation for treatment of H3 K27M mutant glioma ▪ Potential to receiv

  18. Slide 18: Promising pipeline in development

    18 Promising pipeline in development ONC206 : ▪ Differentiated DRD2 antagonist + ClpP agonist ▪ Phase 1 for recurrent CNS tumors ONC212 : ▪ GPR132 agonist + ClpP agonist ▪ IND - enabling studies

  19. Slide 19: Deal terms

    19 Deal terms ▪ Acquisition of Oncoceutics, Inc. including ONC201, ONC206 and ONC212 ▪ Financial Terms - Upfront Consideration = $78M • $39M in equity ~8.7M shares • $39M in cash ($14M deferred for one year) - Milestones (m/s) • Efficacy m/s: $20M with ONC201 BICR 1 ORR 1 ≥ 20% • Regulatory approval

  20. Slide 20: Financial Summary

    20 Financial Summary ▪ Cash balance of approx. $78M at 12/31/2020 ▪ Several levers available for additional capital: - Expected significant non - dilutive proceeds from potential BCV stockpiling in 2021 - Global rights to most programs - Several 2021 catalysts provides additional optionality ▪ ~71 m

  21. Slide 21: Corporate Summary

    21 Corporate Summary

  22. Slide 22: Major, near-term paths to value

    22 Major, near - term paths to value ▪ Final steps toward BCV (smallpox) potential commercialization - NDA filed, April 7, 2021 PDUFA date - Satisfies second mandate for 2 nd countermeasure for strategic national stockpile - Potential $80 - $100m annual cash flow for next 5 - 12 years ▪ Synergistic

  23. Slide 23: Deep pipeline across all development stages

    23 Program Collaborators Preclinical Phase 1 Phase 2 Registrational FDA review Deep pipeline across all development stages IND enabling studies ONC212 ONC201 H3 K27M - mutant glioma (orphan drug designation) 1 Neuroendocrine (PCPG) 2 DSTAT Acute Myeloid Leukemia (orphan drug designation) COVID - 19

  24. Slide 24: Delivery of 2020 objectives sets stage for catalyst rich 2021

    24 DSTAT AML: x End of Ph2 FDA meeting x Confirm endpoint/Ph3 design COVID - 19 Acute Lung Injury: x IND; FDA alignment of Ph2/3 design, endpoint x Ph2/3 study initiation AML: ▪ Planned initiation of Ph3 study COVID - 19 Acute Lung Injury: ▪ Final data on Ph2 trial ▪ Potential initiation of Ph3 stud

  25. Slide 25: Accelerating development through disciplined investment

    25 Accelerating development through disciplined investment Source of non - dilutive capital directed toward innovative oncology development Focus on oncology areas of high unmet need supported by strong clinical data BCV for strategic national stockpile – smallpox outbreak preparation, PDUFA date Ap

  26. Slide 26: Acquisition of Oncoceutics Adds Precision Oncology Pipeline with Near-term Registration Potential

    Acquisition of Oncoceutics Adds Precision Oncology Pipeline with Near - term Registration Potential

Chimerix — Merger or Acquisition (January 2021) on 6ix